Dawnrays Pharmaceutical Holdings Ltd. (HK:2348) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dawnrays Pharmaceutical Holdings Ltd. announced the appointment of Ms. Yu Liwei as the new CEO, effective from 13 September 2024. Ms. Yu, with a background in Biological Pharmaceutics and a history of managerial roles within the company, steps into the leadership position with a two-year contract. Her compensation includes an annual salary of HKD2,400,000 plus potential discretionary bonuses based on the company’s performance.
For further insights into HK:2348 stock, check out TipRanks’ Stock Analysis page.